Want to see MAZE full AI Analyst Report?
MAZE Stock Chart & Stats
$28.09
--
Market closed
$28.09
--
Day’s Range― - ―
52-Week Range$12.81 - $53.65
Previous CloseN/A
VolumeN/A
Average Volume (3M)745.45K
Market Cap
$1.56B
Enterprise Value$1.32K
Total Cash (Recent Filing)$352.38M
Total Debt (Recent Filing)$61.22M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Aug 18, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.75
Shares Outstanding55,345,260
10 Day Avg. Volume611,492
30 Day Avg. Volume745,450
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.02
Price to Sales (P/S)0.00
P/FCF Ratio-15.79
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$70.00Price Target Upside149.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.73
Revenue Forecast (FY)$22.22M
Bulls Say, Bears Say
Bulls Say
Low Leverage & Equity CushionMaze's balance sheet shows low leverage and a sizable equity buffer, giving the company structural financial flexibility. This reduces short-term insolvency risk, supports continued R&D investment, and allows management to pursue clinical milestones without immediate debt pressure.
Extended Runway From $150M OfferingThe $150M financing materially extends cash runway into 2029, lowering near-term financing risk and enabling multi-year clinical programs. This provides durable funding to advance lead candidates (MZE829, MZE782) through key development inflection points before needing additional capital.
Board & Audit ContinuityRecent director elections and auditor ratification reinforce governance stability and external oversight. Continuity at the board and audit levels supports consistent strategic execution and investor confidence during clinical development cycles, a durable governance positive.
Bears Say
Sustained Cash BurnMaze has persistent, large negative operating and free cash flow, which structurally requires external financing until product revenues or margins improve. Ongoing cash burn raises strategic execution risk and forces periodic capital raises that can dilute shareholders and divert management focus.
Large Net Loss & Negative Operating ProfitThe company runs a cost structure far above current revenue, generating substantial net losses and negative operating profit. This undermines profitability durability and means operational scalability and margin sustainability remain unproven across the typical biotech funding cycle.
Volatile, Non-Durable RevenuesRevenue has been highly volatile year-to-year, with 2024 an outlier. Such swings make forecasting and commercialization planning difficult, increasing reliance on financing events. Structural revenue instability raises execution risk for transitioning to sustainable, predictable cash generation.
Maze Therapeutics, Inc. News
MAZE FAQ
What was Maze Therapeutics, Inc.’s price range in the past 12 months?
Maze Therapeutics, Inc. lowest stock price was $12.81 and its highest was $53.65 in the past 12 months.
What is Maze Therapeutics, Inc.’s market cap?
Maze Therapeutics, Inc.’s market cap is $1.56B.
When is Maze Therapeutics, Inc.’s upcoming earnings report date?
Maze Therapeutics, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 29 days.
How were Maze Therapeutics, Inc.’s earnings last quarter?
Maze Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -$0.45 earnings per share for the quarter, beating the consensus estimate of -$0.577 by $0.127.
Is Maze Therapeutics, Inc. overvalued?
According to Wall Street analysts Maze Therapeutics, Inc.’s price is currently Undervalued.
Does Maze Therapeutics, Inc. pay dividends?
Maze Therapeutics, Inc. does not currently pay dividends.
What is Maze Therapeutics, Inc.’s EPS estimate?
Maze Therapeutics, Inc.’s EPS estimate is -0.72.
How many shares outstanding does Maze Therapeutics, Inc. have?
Maze Therapeutics, Inc. has 55,345,260 shares outstanding.
What happened to Maze Therapeutics, Inc.’s price movement after its last earnings report?
Maze Therapeutics, Inc. reported an EPS of -$0.45 in its last earnings report, beating expectations of -$0.577. Following the earnings report the stock price went up 4.577%.
Which hedge fund is a major shareholder of Maze Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MAZE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Maze Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$70.00 (149.20% Upside)
$70.00 (149.20% Upside)
Blogger Sentiment
Bullish
MAZE Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 214.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 2.5%
Last 30 Days ▲ 6.0%
Last 30 Days ▲ 6.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
64.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
26.10%
Trailing 12-Months
Company Description
Maze Therapeutics, Inc.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
MAZE Stock 12 Month Forecast
Average Price Target
$70.00
▲(149.20% Upside)
Technical Analysis
Ownership Overview
11.08% Insiders
5.52% Mutual Funds
<0.01% Other Institutional Investors
74.62% Public Companies and
Individual Investors